Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia  by Cerami, Chiara et al.
NeuroImage: Clinical 7 (2015) 187–194
Contents lists available at ScienceDirect
NeuroImage: Clinical
j ourna l homepage: www.e lsev ie r .com/ locate /yn ic lBrain metabolic maps in Mild Cognitive Impairment predict
heterogeneity of progression to dementiaChiara Ceramia,b,c,⁎, Pasquale Anthony Della Rosad, Giuseppe Magnanie, Roberto Santangeloe,
Alessandra Marconec, Stefano F. Cappaf, Daniela Perania,b,d,g
aUniversità Vita-Salute San Raffaele, Milan, Italy
bDivision of Neuroscience, San Raffaele Scientiﬁc Institute, Milan, Italy
cClinical Neuroscience Department, Neurorehabilitation Unit, San Raffaele Hospital, Milan, Italy
dIstituto di Bioimmagini e Fisiologia Molecolare C.N.R., Segrate, Italy
eDepartment of Neurology, San Raffaele Hospital, Milan, Italy
fIstituto Universitario degli Studi Superiori, Pavia, Italy
gNuclear Medicine Unit, San Raffaele Hospital, Milan, Italy* Corresponding author at: Università Vita-Salute San R
20134, Italy. Tel.: 0039 02 26435760; fax: 0039 02 26415
E-mail address: cerami.chiara@hsr.it (C. Cerami).
http://dx.doi.org/10.1016/j.nicl.2014.12.004
2213-1582/© 2014 Published by Elsevier Inc. This is an opa b s t r a c ta r t i c l e i n f oArticle history:
Received 15 April 2014
Received in revised form 27 July 2014
Accepted 1 December 2014
Available online 5 December 2014
Keywords:
Mild Cognitive Impairment
[18F]FDG
PET imaging
Dementia diagnosis
Alzheimer3s disease[18F]FDG-PET imaging has been recognized as a crucial diagnostic marker in Mild Cognitive Impairment (MCI),
supporting the presence or the exclusion of Alzheimer3s Disease (AD) pathology. A clinical heterogeneity, how-
ever, underlies MCI deﬁnition. In this study, we aimed to evaluate the predictive role of single-subject voxel-
based maps of [18F]FDG distribution generated through statistical parametric mapping (SPM) in the progression
to different dementia subtypes in a sample of 45 MCI. Their scans were compared to a large normal reference
dataset developed and validated for comparison at single-subject level. Additionally, Aβ42 and Tau CSF values
were available in 34MCI subjects. Clinical follow-up (mean 28.5± 7.8months) assessed subsequent progression
to AD or non-AD dementias. The SPM analysis showed: 1) normal brain metabolism in 14 MCI cases, none of
them progressing to dementia; 2) the typical temporo-parietal pattern suggestive for prodromal AD in 15
cases, 11 of them progressing to AD; 3) brain hypometabolism suggestive of frontotemporal lobar degeneration
(FTLD) subtypes in 7 and dementiawith Lewy bodies (DLB) in 2 subjects (all fulﬁlled FTLD or DLB clinical criteria
at follow-up); and 4) 7 MCI cases showed a selective unilateral or bilateral temporo-medial hypometabolism
without the typical AD pattern, and they all remained stable. In our sample, objective voxel-based analysis of
[18F]FDG-PET scans showed high predictive prognostic value, by identifying either normal brain metabolism or
hypometabolic patterns suggestive of different underlying pathologies, as conﬁrmed by progression at follow-
up. These data support the potential usefulness of this SPM [18F]FDG PET analysis in the early dementia diagnosis
and for improving subject selection in clinical trials based on MCI deﬁnition.
© 2014 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Mild Cognitive Impairment (MCI) is an umbrella term used to iden-
tify a transitional condition between normal cognitive functioning and
dementia, in most cases Alzheimer3s Disease (AD) (Albert et al., 2011).
Cognitive impairment may be either isolated or involvingmultiple cog-
nitive domains (Petersen et al., 2009; Kawashima et al., 2012). Up to
30% of subjects presents with the amnestic subtype. Compared to the
estimated incidence of dementia in the normal elderly population
(1–2% per year), the rate of progression in AD is much higher for the
MCI subjects (10–15% per year) (Petersen et al., 2009). Longitudinalaffaele, Via Olgettina 60, Milan
738.
en access article under the CC BY-NCstudies on MCI provided evidence for different possible progressions,
ranging from the development of AD or non-AD dementias to the stabi-
lization or even the reversion of cognitive impairments (Mitchell &
Shiri-Feshki, 2009; Schroeter et al., 2009; Galluzzi et al., 2013). This clin-
ical heterogeneity might reﬂect a variety of underlying neuropatholog-
ical conditions (Petersen et al., 2009). In this view, MCI deﬁnition
presents broad boundaries and goes much more beyond the so-called
prodromal stage of AD (Dubois et al., 2010).
In clinical practice, even if the fulﬁllment of MCI condition is deter-
mined through clinical–neuropsychological judgment, a variable com-
bination of instrumental tools may offer substantial information on
the possible underlying pathology, allowing the recognition of prodro-
mal AD cases or other causes of cognitive decline. In the last years,
however, researchers mainly focused on the early diagnosis of the
MCI caused by AD (or prodromal AD) rather than on the clinical-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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AD (Albert et al., 2011; Jack et al., 2011; Sperling et al., 2011) incorpo-
rated markers of Aβ42 protein deposition (i.e., cerebrospinal ﬂuid
(CSF) Aβ42 and [11C]PiB-PET imaging) and markers of neurodegenera-
tion (i.e., CSF, Tau, reduction of glucose metabolism in temporo-parietal
cortex by [18F]FDG-PET imaging, and hippocampal or medial temporal
atrophy on MRI) (Herholz, 2010; McKhann et al., 2011; Jack, 2013).
Similarly, the IWG criteria for prodromal AD require the positivity of
biomarkers, in association with the presence of hippocampal-type
memory dysfunction (Dubois et al., 2014).
[18F]FDG-PET has been recognized as a crucial diagnostic marker in
dementia since the early disease phases, predicting the possible pro-
gression to AD in MCI subjects (Anchisi et al., 2005; Chételat et al.,
2005; Mosconi, 2005; Mosconi et al., 2008; Fouquet et al., 2009;
Patterson II et al., 2010; Brück et al., 2013; Dukart et al., 2013;
Hatashita & Yamasaki, 2013; Prestia et al., 2013), and allowing the ex-
clusion of AD pathology (Silverman et al., 2008; Ossenkoppele et al.,
2013). The typical AD metabolic pattern was shown even years before
the disease onset, as proven in dominantly inherited AD (Bateman
et al., 2012) and in familial sporadic cases (Mosconi et al., 2014).
In a memory clinic setting, molecular imaging has provided signiﬁ-
cant value over standard diagnostic work-up, inﬂuencing the ﬁnal diag-
nosis (Sánchez-Juan et al., 2014). This is especially true when prior
diagnostic conﬁdence is low (Ossenkoppele et al., 2013). Although
both amyloid-PET and [18F]FDG-PET imaging might predict progression
to AD in prodromal patients, FDG imaging provides extra information.
By recognizing speciﬁc patterns of cerebral glucose hypometabolism,
it can differentiate among major neurodegenerative diseases and de-
mentia subtypes, according to the topographic distribution of metabolic
changes (Teune et al., 2010; Perani, 2013).
Compared to amyloid-PET that provides a basic dichotomous infor-
mation (AD vs. non-ADpathology), [18F]FDG-PET imaging can be partic-
ularly useful in predicting the differential progression of MCI condition.
It is extremely useful for the early differential diagnosis in dementia
conditions as it is closely related to severity, progression and type of
cognitive impairment. Medial temporal and parietal hypometabolism
on [18F]FDG-PET imagingmay also predict clinical progression of elderly
normal intomild cognitive impaired subjects (Ewers et al., 2014).More-
over, combining [18F]FDG-PET information with clinical–neuropsycho-
logical data is also of particular utility for prognostic purposes in MCI
subjects (Perani, 2008, 2013; Pagani et al., 2010). In addition, as recently
showed by Rabinovici et al. (2011), the adoption of semi-quantitative
measurements of [18F]FDG-PET scan can increase speciﬁcity (from 84%
to 98%) in the differential diagnosis betweenAD andnon-ADdementias,
namely frontotemporal lobar degeneration (FTLD) in the above-
mentioned study.
In this study, we assessed the role of [18F]FDG-PET imaging in the
diagnostic ﬂow chart of MCI subjects, evaluating the consistency of
hypometabolic patterns at baseline in terms not only to correct predic-
tion of possible progression to AD, but also to non-AD dementia sub-
types on the basis of clinical classiﬁcation at follow-up. In order to
obtain higher diagnostic accuracy, we measured [18F]FDG-PET scansTable 1
Clinical and demographical features of patients3 sample.
All
Patients (male) 45 (19)
Age in years (mean ± SD) 70.6 ± 5.7
Education in years (mean ± SD) 11.1 ± 3.7
Months from symptoms onset to baseline visit (mean ± SD) 36.4 ± 26.4
Follow-up in months (mean ± SD) 28.5 ± 7.8
MMSE raw score (mean ± SD) 26.7 ± 1.9
a-MCI=amnestic single domainMCI; na-MCI=non-amnestic single domainMCI;md-MCI=a
a-MCI N md-MCI; na-MCI N md-MCI.with an objective voxel-based Statistical Parametrical Mapping (SPM)
procedure (Della Rosa et al., 2014) and used a large.
2. Materials and methods
2.1. Subjects
Forty-ﬁveMCI subjects (19men, 26 women;mean age= 70.5 years
and standard-deviation [SD] = 5.7; CDR = 0.5) were included in the
study (Table 1). They were recruited at the San Raffaele Scientiﬁc Insti-
tute (Milan, Italy), referringwithmemory or othermild cognitive disor-
ders, and evaluated by a team of experienced behavioral neurologists
and neuropsychologists with a structured clinical interview, a full neu-
rological examination, and a standard neuropsychological battery. MCI
condition was deﬁned as the presence of objective impairment at neu-
ropsychological evaluation in memory or other cognitive domains in
the absence of functional impairment and no dementia (Petersen
et al., 2009; Albert et al., 2011). All patients underwent clinical and neu-
ropsychological follow-up visits every 6 months in order to evaluate
possible decline. The neuropsychological battery included measures of
short- and long-term verbal–auditory and visuo-spatial memory, exec-
utive functions, language domain and visuo-spatial abilities, as well as a
neurobehavioral assessment. In particular, global cognitive functioning
(Mini-Mental State Examination), memory and executive functions
(Rey Auditory Verbal Learning Test; Rey3s Figure Recall Test; Verbal
and Visual Digit Span Task; Attentive Matrices; Raven3s Progressive
Matrices) (seeLezak, 2000for details), language abilities (Phonological
and Semantic Fluency; Token test (De Renzi & Vignolo, 1962); Aachener
Aphasie Test (AAT) (Luzzatti et al., 1994) or “Batteria per l3analisi dei
deﬁcit afasici” (BADA) (Miceli et al., 1994) subtests), and visuo-
perceptual and visuo-spatial abilities (Rey3s ﬁgure copy test) (seeLezak,
2000) were assessed in each patient. Speciﬁc tasks (e.g. Pyramids and
Palm-tree Task (Gamboz et al., 2009); Visual Object and Space Percep-
tion Battery (VOSP) (Warrington & James, 1991) subtests) were admin-
istered only in speciﬁc cases. Neuropsychiatric Inventory (Cummings
et al., 1994) and Frontal Behavioral Inventory (Kertesz et al., 1997;
Alberici et al., 2007)were administered to caregivers in order to exclude
signiﬁcant behavioral symptoms. No case showed signiﬁcant positive
(e.g. aggressiveness, disinhibition or psychotic disorders) or negative
(e.g. loss of empathy or sympathy) behavioral changes. Mild to moder-
ate anxiety and apathywere reported in some cases. No subject present-
ed with extrapyramidal signs, apraxia or aphasia at the neurological
examination; and few subjects complained of anomia. None reported
sleep disorders.
In 34 out of 45 subjects, CSF Aβ42, total Tau (t-Tau) and phosphory-
lated Tau (p-Tau) values were obtained by lumbar puncture during the
hospitalization. After centrifugation, CSF samples were stored at−80 °C
until the analysis. Then, measurements of Aβ42, t-Tau and p-Tau were
performed in the local laboratory by technicians blinded to the clinical
diagnosis, using a commercially available ELISA kits (Innogenetics®,
Gent, Belgium), according to the manufacturer3s instructions. Cut-off
values for AD reported in the literature (Tapiola et al., 2009) werea-MCI na-MCI md-MCI Statistics
22 (7) 8 (2) 15 (10) −
70.8 ± 5.9 71.5 ± 7.1 69.8 ± 4.9 NS
11.2 ± 3.8 11.6 ± 3.7 10.9 ± 3.7 NS
41.5 ± 31.8 28 ± 13 33.4 ± 22.4 NS
28.9 ± 9.5 29.3 ± 6.3 27.4 ± 5.9 NS
28.1 ± 0.8 26.3 ± 0.9 25.1 ± 1.6 p = 0.0000 *
mnesticmultidomainMCI;MMSE=Mini-Mental State Examination; *= a-MCIN na-MCI;
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Tau = 0–61 ng/L. Typical AD proﬁle was considered the presence of
both Aβ42 and t-Tau/p-Tau and atypical CSF proﬁle for AD either the
reduction of Aβ42 only or the increase of t-Tau/p-Tau with normal
values of Aβ42.
On the basis of the neuropsychological presentation, theMCI sample
was sub-grouped at the baseline visit into 22 amnestic single domain
(a-MCI), 15 amnestic multidomain (md-MCI) and 8 non-amnestic sin-
gle domain (na-MCI) (3 dysexecutive and 5 visuo-spatial) subjects.
See Tables 1 and 2 for more details on the MCI sample.
The clinicians were blinded to [18F]FDG-PET data (i.e., no informa-
tion about either the distribution of FDG-uptake or the visual reading
of SPM results, and no access to the scans themselves) during all the
follow-up period, and the possible progression to dementia was classi-
ﬁed according to current clinical criteria for each neurodegenerative
dementia subtype (McKeith et al., 2005; Dubois et al., 2010; Gorno-
Tempini et al., 2011; McKhann et al., 2011; Rascovsky et al., 2011;
Armstrong et al., 2013).
All subjects and their informants/caregivers gave informed consent
to the experimental procedure that had been approved by the local Eth-
ical Committee.Table 2
Demographic data, clinical features and instrumentalﬁndings of eachMCI patient.M=male; F=
na-MCI = non-amnestic single domain MCI; md-MCI = amnestic multidomain MCI.
Patient
number
Gender Age Education MMSE Months from ﬁrst
symptoms to baseline
Diagnosi
baseline
#1 M 66 13 24 36 md-MCI
#2 F 75 13 27 24 a-MCI
#3 F 62 8 27 18 a-MCI
#4 F 74 8 29 12 a-MCI
#5 F 58 12 28 130 a-MCI
#6 F 60 8 27 24 a-MCI
#7 M 74 8 30 36 a-MCI
#8 M 68 5 29 132 a-MCI
#9 F 69 8 26 26 md-MCI
#10 M 67 13 25 108 md-MCI
#11 M 77 13 27 60 a-MCI
#12 M 70 12 26 24 na-MCI
#13 F 69 13 28 38 a-MCI
#14 F 75 11 26 20 na-MCI
#15 F 79 11 28 36 a-MCI
#16 M 77 11 25 24 md-MCI
#17 F 61 8 28 60 na-MCI
#18 F 71 5 28 24 a-MCI
#19 M 68 12 24 12 a-MCI
#20 F 66 15 26 24 na-MCI
#21 M 83 17 27 23 na-MCI
#22 M 66 8 29 12 a-MCI
#23 M 63 8 28 36 md-MCI
#24 F 62 8 24 25 md-MCI
#25 M 77 13 27 48 a-MCI
#26 F 79 12 26 26 na-MCI
#27 M 73 8 28 36 a-MCI
#28 F 72 12 28 24 a-MCI
#29 M 73 8 23 24 md-MCI
#30 F 68 12 27 24 na-MCI
#31 M 73 6 27 36 md-MCI
#32 M 74 17 24 24 md-MCI
#33 M 70 10 28 48 md-MCI
#34 F 70 13 25 23 na-MCI
#35 F 63 8 23 19 md-MCI
#36 F 72 17 25 24 md-MCI
#37 M 72 17 24 36 md-MCI
#38 F 80 17 28 25 a-MCI
#39 F 74 13 29 60 a-MCI
#40 M 75 5 27 40 a-MCI
#41 F 73 17 29 26 a-MCI
#42 F 70 18 29 34 a-MCI
#43 F 78 8 26 24 md-MCI
#44 F 69 16 29 50 a-MCI
#45 F 64 8 28 24 a-MCI2.2. [18F]FDG-PET image acquisition and analysis
All [18F]FDG-PET acquisitions were performed for diagnostic re-
search purposes at the NuclearMedicine Unit, San Raffaele Scientiﬁc In-
stitute (Milan, Italy) following standardized procedures (Anchisi et al.,
2005) within 6months from the ﬁrst baseline clinical visit. In particular,
before radiopharmaceutical injection of [18F]FDG (185–250Mbq: usually,
5–8 mCi via a venous cannula), subjects were fasted for at least 6 h and
measured blood glucose level threshold was b120 mg/dL. All images
were acquired with a Discovery STE (GE Medical Systems, Milwaukee,
WI) multi-ring PET tomography (PET-CT) system (time interval between
injection and scan start = 45 min; scan duration = 15 min).
Images were reconstructed using an ordered subset expectation
maximization (OSEM) algorithm. Attenuation correction was based on
CT scan. Speciﬁc software integrated in the scanner was used for scatter
correction. Subjects3 scans were obtained at resting state in a relaxed
and comfortable position. All subjects gave written informed consent,
following detailed explanation of the [18F]FDG-PET procedure.
Image pre-processing and statistical analysis were performed using
SPM5 (http://www.ﬁl.ion.ucl.ac.uk/spm/software/spm5). Single patient
[18F]FDG-PET scans were normalized according to the procedurefemale;MMSE=Mini-Mental State Examination; a-MCI=amnestic single domainMCI;
s at the Time of
follow-up
Diagnosis at the
follow-up
PET
pattern
CSF
Abeta
CSF
t-Tau
CSF
p-Tau
24 md-MCI Negative 630 122 30
36 a-MCI Negative 557 148 41
40 a-MCI Negative 793 428 87
32 a-MCI Negative 750 233 51
24 a-MCI Negative 529 154 44
18 a-MCI Negative 701 220 62
22 a-MCI Negative 1237 277 84
15 a-MCI Negative 542 101 26
27 md-MCI Negative − − −
33 md-MCI Negative 580 185 51
27 a-MCI Negative 847 379 84
40 na-MCI Negative 931 289 75
28 a-MCI Negative 493 242 61
20 na-MCI Negative − − −
26 AD AD-like 754 557 163
19 md-MCI AD-like 453 313 82
30 AD AD-like 204 226 56
60 AD AD-like 243 370 24
27 AD AD-like 227 899 102
22 AD AD-like − − −
33 AD AD-like − − −
24 AD AD-like 424 200 61
18 AD AD-like 331 477 120
32 AD AD-like 253 347 84
27 AD AD-like 274 199 61
32 md-MCI AD-like − − −
31 md-MCI AD-like 194 543 133
20 a-MCI AD-like − − −
26 AD AD-like − − −
28 bvFTD bvFTD-like − − −
36 bvFTD bvFTD-like 924 275 54
19 md-MCI bvFTD-like 663 497 89
33 bvFTD bvFTD-like 491 241 71
30 bvFTD bvFTD-like − − −
29 sv-PPA sv-PPA-like 557 132 37
36 CBD CBD-like − − −
23 DLB DLB-like 336 676 132
25 DLB DLB-like − − −
38 AD mTLD-like 407 531 107
20 md-MCI mTLD-like 429 163 41
32 a-MCI mTLD-like 372 373 28
26 a-MCI mTLD-like 422 176 43
29 md-MCI mTLD-like 232 418 80
30 AD mTLD-like 270 339 70
36 a-MCI mTLD-like 437 489 105
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template (Della Rosa et al., 2014) for spatial normalization of [18F]FDG-
PET scans. This is an optimized method that showed increased reliability
and accuracy of estimated metabolic activity patterns compared to the
standard [15O]H2O-PET template currently available for SPM normaliza-
tion procedures. Indeed, it allows to better recognize relevant metabolic
changes that may otherwise be obscured by spatial normalization. Each
patient scan was tested for relative ‘hypometabolism’ by comparison
with a normal reference [18F]FDG-PET dataset ad hoc developed and
validated (Perani et al., 2014). The dataset included a selection of [18F]
FDG-PET of healthy controls either from European Alzheimer Disease
Consortium (EADC)-PET and from the San Raffaele Hospital normal data-
base. Cognitive healthwas established in each EADC-PET center bymeans
of a structured clinical and a neuropsychological battery as speciﬁed in a
previous paper (Morbelli et al., 2012). The inter-scanner differences
were accounted for by using a large number of subjects. Thiele and co-
workers (Thiele et al., 2013), evaluating the impact of using healthy
subjects from different PET scanners on the accuracy of voxel-based clas-
siﬁcation of [18F]FDG-PET in AD diagnosis, found that a larger number of
control cases correspond to higher accuracy. In particular, Thiele et al.
showed that the accuracy of classiﬁcation reached 91% when a larger
set including images from a different PET scanner was considered.
Noteworthy, a validation for different PET scan in [18F]FDG assessment
using SPM has been reported by our group (Gallivanone et al., 2014).
Age was included in the two sample T-test analysis as a covariate.
Due to the lack of any signiﬁcant difference in metabolic activity of
male and female Alzheimer patients (Minoshima et al., 1997), gender
was not controlled in the analysis. Proportional scaling was used to re-
move intersubject global variation in PET intensities, according to
Signorini et al. (1999). Additionally, voxel-wise comparisons were
made using a within-brain comparison-speciﬁc explicit [18F]FDG mask
(Ridgway et al., 2009) in order to remove emission counts outside of
the brain and to restrict subsequent analyses to within-brain voxels
(Spence et al., 2006). The “hypometabolic” SPM t-map was the basis for
deﬁning disease-speciﬁc patterns. The threshold was set at p = 0.05,
FWE-corrected for multiple comparisons at the voxel level. Only clusters
containing more than 100 voxels were deemed to be signiﬁcant.
2.3. Statistical validation of [18F]FDG-PET hypometabolic patterns for the
classiﬁcation and differentiation of MCI patients
All [18F]FDG-PET scans were retrospectively evaluated and indepen-
dently classiﬁed by two expert raters. Both raters were blinded to base-
line clinical–neuropsychological data and to the diagnostic classiﬁcation
at the follow-up.Since each subject underwent a CT/PET scan, the raters
were able to visually assess the brain atrophy.
Raters were ﬁrst asked to specify whether the SPM-t map was nor-
mal or abnormal. Namely, a normal SPM-t map should not reveal any
signiﬁcant hypometabolic pattern at a FWE-corrected threshold, either
at the voxel or the cluster level. Then, raters were asked to describe
brain hypometabolism reporting the possible involvement of speciﬁc
brain areas. Thus, they had to decide whether the hypometabolic pat-
tern was suggestive of a speciﬁc neurodegenerative dementia subtype,
according to a well-established literature (Salmon et al., 2003; Anchisi
et al., 2005; Franceschi et al., 2005; Juh et al., 2005; McKeith et al.,
2005; Herholz et al., 2010; Teune et al., 2010; Gorno-Tempini et al.,
2011; Rascovsky et al., 2011; Crutch et al., 2012; Armstrong et al.,
2013). Each patient scan thus received a label indicating whether it
did not satisfy the criteria for the diagnosis of dementia (i.e., negative
scan) or it was compatible with AD, dementia with Lewy-bodies
(DLB) or FTLD subtypes.In particular, SPM-t maps were classiﬁed as
AD-like pattern when they showed: a) bilateral temporo-parietal
hypometabolism and/or involvement of precuneus/posterior cingulate
cortex, namely the typical AD pattern (Herholz et al., 2002; Anchisi
et al., 2005; Teune et al., 2010), b) asymmetric posterior perisylvian/
parietal hypometabolism, which is the metabolic signature ofatypical AD/logopenic variant of PPA (Gorno-Tempini et al., 2011),
and c) temporo-parietal and occipital involvement, associated with
hypometabolic foci in the frontal eye ﬁeld regions, which characterizes
the atypical AD/posterior cortical atrophy syndrome (Crutch et al., 2012;
Cerami et al., 2015). Medial and lateral occipital cortex hypometabolism
(McKeith et al., 2005; Teune et al., 2010), accompanying various degrees
of temporo-parietal and frontal cortex dysfunction, was considered as
suggestive of DLB-like pattern.In the FTLD spectrum, the following
FTLD-like patterns were considered: a) prevalent involvement of the
anterior cingulate cortex, ventromedial and/or dorsolateral frontal
cortex, and orbito-frontal cortex as typical of the behavioral variant
of frontotemporal dementia (bvFTD) (Salmon et al., 2003; Franceschi
et al., 2005; Teune et al., 2010; Rascovsky et al., 2011); b) predominant
temporal pole, anterolateral temporal cortex, either bilateral or unilateral,
hypometabolism, as typical of the semantic variant of PPA (sv-PPA)
(Gorno-Tempini et al., 2011); c) left fronto-insular hypometabolism in
the case of non-ﬂuent variant of PPA (nf-PPA) (Gorno-Tempini et al.,
2011); d) asymmetric fronto-parietal hypometabolism with speciﬁc
involvement of the parietal operculum as typical pattern of corticobasal
degeneration (CBD) (Juh et al., 2005; Armstrong et al., 2013); and
e) frontal–medial and frontal opercular hypometabolism with additional
involvement of subcortical structures (thalamus and midbrain) as possi-
ble pattern of progressive supranuclear palsy (PSP) (Juh et al., 2005;
Armstrong et al., 2013). An isolated hypometabolic pattern involving
themedial temporal lobe (i.e., hippocampus, parahippocampal and ento-
rhinal gyri) was also present in someMCI cases. Raters classiﬁed this me-
dial temporal lobar dysfunction (mTLD)-like pattern separately (Marra
et al., 2012; Whitwell et al., 2012).We calculated the inter-rater agree-
ment level, and found comparable levels (k=0.895), showing an “almost
perfect agreement” between the two raters.In order to infer the probabil-
ity of a single case of a having or not a speciﬁc targeted disease condition
after a diagnostic test, we used the positive and negative “Post-test Prob-
ability” (i.e., the probability of developing or not developing a speciﬁc de-
mentia subtype). Positive Post-test Probability should be intended as the
probability of an individual of developing the condition of interest in the
future and not of having the disease. The same, in the case of a negative
test, applies to the Negative Post-test Probability.
3. Results
3.1. Single-subject voxel-based hypometabolic maps
Fourteen subjects (9 a-MCI, 3 md-MCI, 1 visuo-spatial na-MCI, and 1
dysexecutive na-MCI) showed normal brain metabolism. Fifteen cases
(6 a-MCI, 5 md-MCI, and 4 na-MCI visuospatial) had an AD-like pattern.
Twelve out of 15 subjects presented with a bilateral temporo-parietal
hypometabolism, and/or precuneus/posterior cingulate cortex, while
the remaining 3 showed a predominant left asymmetric hypometabolism
mainly involving posterior perisylvian/parietal regions. Seven patients
(5 md-MCI, 2 na-MCI dysexecutive) showed an FTLD-like pattern. Five
of them presented the typical PET pattern of bvFTD, while the remain-
ing two cases showed, respectively CBD and sv-PPA PET pattern. Two
MCI patients (1 a-MCI and 1 md-MCI with memory and visuo-spatial
impairments) presented a DLB-like pattern. See Fig. 1 for some exam-
ples of the AD-like, DLB-like, and FTLD-like PET patterns and Table 2
for details on clinical and instrumental ﬁndings of each subject.
The remaining seven MCI patients (1md-MCI and 6 a-MCI) showed
an mTLD-like pattern (Fig. 2A). Noteworthy, on visual inspection of CT
or MRI scan, all these patients showed concomitant mild to severe me-
dial temporal atrophy (see Fig. 2B).
CSF evaluation, performed in 34/45 MCI patients, documented
1) typical AD values in 12 patients, 2) either lowAβ42 (n=5) or elevat-
ed t-Tau and p-Tau (n = 7) in 12 patients, and 3) normal CSF bio-
markers value in the remaining 10. None of the subjects with normal
CSF values presented an AD-like pattern and none of the MCI cases
with negative SPM-t map, for which CSF was available (12/14 cases),
Fig. 1. The SPM-t maps of hypometabolism of eight MCI cases, as example: PET patterns corresponding to Alzheimer3s disease (A, B), behavioral variant of frontotemporal dementia (C, D), se-
mantic variant of primary progressive aphasia (E), corticobasal degeneration (F), dementiawith Lewybodies (G, H). Yellow/red scales shown in SPMmaps are regionswhich are hypometabolic
in MCI patient in comparison to the normal control database (see text for details).
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pattern showed low Aβ42 values (seeTable 2for details on single
cases). At the clinical follow-up (mean 28.5 ± 7.8 months), 11/15
cases with AD-like pattern and 2/8 subjects with mTLD-like pattern
converted to AD; none of the caseswith negative SPM-tmap progressed
to dementia. Both subjects with DLB-like pattern developed within
6 months from the baseline further cognitive decline, with ﬂuctuating
cognition and/or hallucination, extrapyramidal signs and loss of func-
tionality. Thus, at the follow-up theywere classiﬁed as probable DLB, ful-
ﬁlling theMcKeith criteria (McKeith et al., 2005). Four up to ﬁve subjects
with bvFTD-like pattern and predominant executive dysfunctions at the
neuropsychological assessment developed frank behavioral disorders
(i.e., apathy and disinhibition, loss of empathy and inappropriate behav-
iors) with relevant loss of functionality during the clinical follow-up.
Their cognitive decline with predominant impairment of frontal and
temporal functions was accompanied with a relative perseveration of
memory and visuo-spatial abilities. Therefore, they fulﬁlled the criteria
for probable bvFTD (Rascovsky et al., 2011). After 18 months from the
baseline visit, the MCI with dysexecutive syndrome and naming impair-
ment and a CBD-like pattern developed asymmetric limb ideomotor
apraxia and extrapyramidal signs. For this reason, according to the cur-
rent criteria (Armstrong et al., 2013), she was classiﬁed at the follow-up
as CBD. Finally, within the ﬁrst year of clinical follow-up, the subject
with long-term memory and naming impairments at the neuropsycho-
logical evaluation, showing an sv-PPA-like pattern, converted to a frank
ﬂuent aphasic syndrome (anomia, semantic disorders, and spared repeti-
tion), compatible with the sv-PPA subtype (Gorno-Tempini et al., 2011).
SeeTable 2for a summary of [18F]FDG-PET patterns and clinical follow-up.3.2. Statistical validation of [18F]FDG-PET hypometabolic patterns for the
classiﬁcation and differentiation of MCI patients
An exact binomial sign test indicated that the [18F]FDG-PET signiﬁ-
cantly classiﬁed 79% of all MCI patients, more often than would be ex-
pected by chance (50%) (p = 0.0025). Five MCI subjects were positive
for a neurodegenerative disease according to SPM-t maps (4 AD-like
and 1 bvFTD-like patterns) but still diagnosed as negative for dementia
(not progressed) at clinical follow-up. No signiﬁcant difference (p =
0.202) in the follow-up time was found between the non-progressing
sample (mean = 24.2 ± 6.7 months) and the MCI subjects which
progressed to AD at follow-up (mean = 29.7 ± 8.7 months).
Within theMCI subjects diagnosedwith a speciﬁc dementia subtype
at clinical follow-up (i.e., AD, DLB or FTLD subtypes) (n= 24), the Pos-
itive Post-test Probability was 100%. This value indicates the probability
of progression to the targeted dementia subtype in the single subject
after the evidence of hypometabolism in the [18F]FDG-PET SPM-t
maps. MCI patients showing negative [18F]FDG-PET SPM-t maps (n =
14), classiﬁed as negative, did not present progression to dementia at
clinical follow-up, hence leading to Negative Post-Test Probability of
100%, as well.4. Discussion
MCI is a heterogeneous condition due to various pathological sub-
strates and characterized by different outcomes (Yaffe et al., 2006;
Fisher et al., 2007; Ganguli et al., 2011). Longitudinal studies on MCI
Fig. 2. The SPM-t map of hypometabolism of an amnestic single domain MCI with mTLD-
pattern displayed on axial view of anMRI standardized structural scan showing a selective
temporo-mesial hypometabolic pattern (A). Axial T1-weighted MRI images showing
mild-moderate selective temporo-mesial atrophy more pronounced on the left side (B).
L = left; R = right.
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from progression to AD or non-AD dementia, to the stabilization or
even to the normalization of cognitive impairment (Mitchell & Shiri-
Feshki, 2009; Han et al., 2012; Galluzzi et al., 2013). Although the out-
come is apparently not consistently related to the clinical subtype of
MCI (Han et al., 2012), the amnestic may be more predictive of incident
dementia, particularly of AD, than the non-amnestic subtype (Petersen
et al., 2009;Ward et al., 2012). Subjects with non-amnestic md-MCI ap-
pear more likely to convert to a non-AD dementia (Busse et al., 2006),
and those with non-amnestic MCI may progress to frontotemporal de-
mentia (Yaffe et al., 2006). Moreover, md-MCI, particularly amnestic,
has been proved to be the subtype that reverts to normal cognition
less frequently (Han et al., 2012).
In this study, using objective voxel-based analysis of [18F]FDG-PET
scan, we provided evidence of distinct patterns of hypometabolism
underlying theMCI condition at the onset. The different patterns predict
the progression of speciﬁc cognitive deterioration at the clinical follow-
up corresponding to different neurodegenerative substrates. In agree-
ment with previous [18F]FDG-PET ﬁndings (Mosconi et al., 2008), we
showed heterogeneous hypometabolic proﬁles among MCI subjects.
Moreover, the typical AD [18F]FDG-PET pattern mostly characterized
the group of md-MCI.
At the clinical follow-up, seven MCI patients of our sample fulﬁlled
the criteria for FTLD subtypes and two for DLB conﬁrming thatMCI con-
dition includes patients at risk for progression to non-AD dementias.
Thus, within our sample, statistical analysis revealed that subjects
with speciﬁc pattern at the objective voxel-based analysis of [18F]FDG-PET imaging have a high probability of developing speciﬁc dementia
subtypes, proving further evidence that semi-quantitative analysis of
[18F]FDG-PET imaging has high accuracy in the early identiﬁcation of
disease-speciﬁc patterns that will progress to different dementia condi-
tions (Rabinovici et al., 2011). Our data also showed that subjects with
negative hypometabolic pattern do not progress to dementia at the clin-
ical follow-up. This ﬁnding supports the high speciﬁcity of objective
voxel-based analysis of [18F]FDG-PET scan and its role as exclusionary
test (Silverman et al., 2008; Ossenkoppele et al., 2013). Normal [18F]
FDG uptake in MCI indicates a low chance of progression within
2 years, even in presence of signiﬁcant memory impairment on neuro-
psychological testing, as already reported by our group (Anchisi et al.,
2005).
The ﬁve MCI subjects with positive [18F]FDG PET that did not prog-
ress to dementia in the follow-up time cannot be regarded as false pos-
itives. The positivity of [18F]FDG-PET imaging suggests the presence of
disease in terms of hypometabolism even in the absence of dementia.
In these cases, higher educational and/or occupational level may be
proxies for brain functional reserve, reducing the severity and delaying
the clinical expression of the underlying pathology, as previously
showed by our group (Garibotto et al., 2008). Nevertheless, a longer
follow-up is needed to evaluate possible progression of cognitive
decline.
Some MCI subjects showed selective medial–temporal dysfunction
without the typical AD hypometabolism in the temporo-parietal,
precuneus/posterior cingulate cortex. On structural imaging, they showed
a concomitant severe atrophy in the same areas. Both these ﬁndings sug-
gest the recently identiﬁed pathological limbic-predominant subtype of
AD (Marra et al., 2012; Whitwell et al., 2012), which is clinically charac-
terized by a prevalent amnestic syndrome, a greater involvement of lim-
bic structures on imaging and higher neuroﬁbrillary tangle counts in the
hippocampus compared to the cortex (Whitwell et al., 2012). In agree-
ment with this view, the subjects in this group presented low CSF Aβ42
values, suggesting anunderlyingADpathology. In linewith previousﬁnd-
ings of a slow rate of progression in subjects with selective focal medial
temporal lobe dysfunction (Marra et al., 2012), our cases showed a
more favorable prognosis notwithstanding a long disease duration
(range 3–8 years), and they did not progress to dementia at the time of
follow-up.
Our results showalso that CSFﬁndingsmostly agreedwith [18F]FDG-
PET imaging in the evaluation of single cases. The majority (n = 9) of
subjects with AD-like PET pattern for which a CSF study was available
(10/15 cases) showed low CSF Aβ42 values. None of the investigated
subjects with negative or non-AD SPM-t maps presented a typical CSF
AD pattern. Further studies are, however, needed to establish the agree-
ment rate between automated voxel-based single-case analysis of [18F]
FDG-PET imaging and CSF Aβ42 and Tau values.
5. Conclusion
Most clinicians estimate the prognosis of MCI on the basis of the
combination of the clinical–neuropsychological features and the results
of structural imaging. The information collected within this scenario is
often insufﬁcient to early diagnose dementia with acceptable conﬁ-
dence, and only longitudinal follow-up might conﬁrm the diagnostic
hypothesis. The use of a second-level diagnostic tool, such as the topo-
graphic biomarker as obtained by [18F]FDG-PET imaging supported by
a voxel-based analysis, allowing the recognition of brain dysfunctional
changes typical of AD or non-AD pathology at the single-subject level,
might improve early diagnosis and prognosis in MCI condition avoiding
multiple examinations over months and years, which may lead to un-
necessary delay in proper management and therapeutic interventions.
The present ﬁndings support the current position that MCI can no
longer be assumed to be a transitional state between normal aging
and AD (Dubois et al., 2010; Albert et al., 2011). While including differ-
ent subtypes of clinical disorders, there are individuals even in the
193C. Cerami et al. / NeuroImage: Clinical 7 (2015) 187–194preclinical phase that may be on a pathway to non-amyloid-based neu-
rodegeneration (Jack et al., 2013; Klunk & Perani, 2013), and amyloid
deposition might be relatively unimportant in these subjects who
could develop non-AD dementia. The correct identiﬁcation of the differ-
ent MCI subtypes and their possible AD or non-AD pathological sub-
strate will be essential also for the implementation of appropriate
therapeutic interventions and for realistic expectations for slowing or
stopping the clinical decline.
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